Screener
TG Therapeutics TGTX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's total equity?
- TG Therapeutics (TGTX) reported total equity of $604.08M in Q2 2026.
- How has TG Therapeutics's total equity changed year-over-year?
- TG Therapeutics's total equity increased by 118.5% year-over-year, from $276.43M to $604.08M.
- What is the long-term trend for TG Therapeutics's total equity?
- Over 5 years (2020 to 2025), TG Therapeutics's total equity has grown at a 4.5% compound annual growth rate (CAGR), from $519.35M to $648.02M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about TG Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude